A Security Risk Assessment Guide for Genetic Variant Interpretation Software Vendors

For vendors, a security risk assessment should examine both the protection of genetic and clinical data and the reliability of the software’s interpretation process. A useful review follows data from upload through analysis, storage, updates, reporting, and deletion, while distinguishing legal requirements from recommended safeguards.

What genetic and clinical data does variant interpretation software process?

Start by mapping what the software receives, creates, displays, and retains. Inputs may include variant call files such as VCF or BCF, sequencing and alignment files such as BAM or CRAM, and annotations drawn from reference databases. Depending on the product, the workflow may also process phenotype terms, family history, pedigrees, clinical notes, test indications, and sample or patient identifiers. The GA4GH-maintained HTS format specifications describe common sequencing and variant-file formats.

Include derived information in the inventory: classifications, evidence summaries, quality-control results, reports, cached results, and support or diagnostic logs. A variant file may contain direct identifiers, sample labels, or information that can be linked with other clinical data. Treat data as sensitive based on its contents and context, not only on whether a name appears in the file.

Do not assume that every genetic-data vendor is automatically subject to HIPAA. HIPAA protections apply to protected health information held by covered entities and their business associates; a vendor’s role and the circumstances in which it handles identifiable health information matter. The National Human Genome Research Institute’s overview of genomic privacy explains that protections depend on how and why information is collected and stored.

How should vendors protect variant files and sensitive clinical information?

Document the data flow and identify where files travel, where they are temporarily processed, which services or subcontractors can access them, and when they are deleted. Collect only the information needed for the intended analysis, separate customer environments, and define secure handling for support access, exports, backups, and test environments. If a vendor handles electronic protected health information for a covered entity or business associate, the parties should assess applicable business-associate obligations and document appropriate assurances.

Use genomic data encryption at rest and encryption in transit as risk-based safeguards, with controlled key access, rotation, and separation of duties. Under the HIPAA Security Rule, encryption is an addressable implementation specification: the regulated entity must assess whether it is reasonable and appropriate and, when it is not, document the decision and consider an equivalent alternative where appropriate. Encryption alone does not address every confidentiality, integrity, or availability risk. See 45 CFR § 164.312 and HHS guidance on encryption under the Security Rule.

Set retention and deletion rules for original files, intermediate data, reports, and backups. If a service provider stores or processes ePHI in the cloud, HHS explains that cloud storage does not remove the provider’s potential business-associate responsibilities and that encryption by itself is not a complete safeguard. Review the service arrangement and responsibilities using HHS guidance on HIPAA and cloud computing.

Which access controls and security safeguards should an assessment review?

Assess whether each user, service account, and administrator receives only the access needed for a defined task. A well-designed role-based access control model can separate clinical users, analysts, customer support, developers, and system administrators. Review unique accounts, strong authentication, multifactor authentication where appropriate, timely access removal, privileged-account monitoring, and periodic access reviews.

For systems subject to HIPAA, the technical safeguards include access control, audit controls, integrity protections, person or entity authentication, and transmission security. The rule requires unique user identification and mechanisms to record and examine activity in systems containing or using ePHI; encryption and automatic logoff are addressable implementation specifications. See 45 CFR § 164.312.

Review safeguards around uploads and processing as well as account access. Variant file input validation should check expected formats, structure, field types, size limits, and consistency with the declared reference assembly before analysis. Reject malformed or unexpected inputs safely, and isolate parsers and analysis jobs so that a bad file cannot affect other customers or systems. Also assess backups, recovery procedures, vulnerability handling, and incident response against the vendor’s documented risk assessment.

How can software updates affect interpretation results and security risk?

An update can change more than the user interface. A new algorithm, filtering rule, annotation source, transcript set, or evidence threshold may change which variants are prioritized or how results are presented. Updates to external databases can also affect the information available for interpretation: NCBI’s ClinVar release documentation describes weekly data updates and monthly archived releases, while its record-version guidance explains how record versions reflect changes.

Maintain reference database versioning and record the reference genome assembly, database release or accession version, annotation sources, software build, and relevant configuration for every analysis. This helps customers reproduce past results and compare them with reanalyses. Before deployment, test changes against representative and edge-case inputs, review regression results, document approval, and provide a rollback path. These are practical controls for preserving reproducibility and limiting unexpected changes; they are not a guarantee that every future classification will remain unchanged.

Updates also change the security posture. Assess code and dependencies for vulnerabilities, control the build and release process, and document security fixes and deployment status. The NIST Secure Software Development Framework recommends integrating secure development practices into the software life cycle to reduce vulnerabilities and help mitigate the effects of flaws that are discovered after release.

What audit records should vendors maintain for analysis and changes?

An effective audit trail retention plan should let an authorized reviewer reconstruct who accessed a record, what analysis ran, which inputs and software versions were involved, and whether anyone changed or exported the result. Depending on the product and risk, useful records may include:

• User or service identity, timestamp, action, and relevant authorization context.
• A pseudonymous sample or case identifier, input-file checksum, and validation outcome.
• Software build, pipeline configuration, reference assembly, database releases, and classification-rule versions.
• Analysis status, output or report identifier, and any manual review, override, or correction, including who made the change and why.
• Administrative changes, access changes, failed access attempts, exports, and security-relevant events.

Protect logs against unauthorized alteration or deletion, restrict access to them, and review them according to a documented process. For HIPAA-regulated systems, the Security Rule requires mechanisms to record and examine activity in systems containing or using ePHI. Its six-year documentation rule applies to documentation required by the Security Rule; do not automatically treat it as a universal six-year retention period for every raw technical log. Confirm applicable contractual, legal, and operational retention needs. See 45 CFR § 164.312 and 45 CFR § 164.316.

How should vendors validate results and address limitations in clinical use?

Assess the software’s intended use, inputs, outputs, and validation evidence separately from the security controls. For classification workflows, document how the product implements the ACMG/AMP variant classification framework, what evidence it uses, how conflicting or insufficient evidence is handled, and where expert review is expected. The joint ACMG/AMP consensus recommendation describes a process for classifying sequence variants into five categories using evidence such as population, computational, functional, and segregation data.

Validation should match the product’s intended use and the populations and data types for which it is intended. Assess input quality checks, analytical behavior, classification logic, handling of missing or conflicting information, and performance across relevant test cases. Explain known limitations in a way that helps users understand what the output does—and does not—establish. In particular, a software prediction is not automatically a clinical assertion; a qualified professional or laboratory process may need to assess the underlying evidence and context.

FDA’s current Clinical Decision Support Software guidance emphasizes that regulatory treatment depends on the software function and intended use. For certain non-device clinical decision support functions, the guidance discusses enabling health professionals to independently review the basis for recommendations, including the inputs, algorithm, validation information, and known limitations. Vendors should assess the specific product and claims rather than assume that all variant interpretation software is treated the same way.

A sound assessment therefore links data protection, reproducible analysis, controlled updates, traceable records, and fit-for-purpose validation. Together, these practices help vendors protect sensitive information while giving users the context needed to evaluate interpretation results responsibly.

FAQs.

Should variant interpretation software predictions be used as the sole basis for a clinical assertion?

No. Treat a software prediction as decision support, not as a substitute for evaluating the evidence, the patient’s context, and relevant professional judgment. FDA guidance for certain clinical decision support functions emphasizes making the basis, validation, and limitations of recommendations available for independent review. See the FDA Clinical Decision Support Software guidance.

What security controls should vendors apply to genetic and clinical data?

Use a risk-based set of controls that may include data minimization, encryption in transit and at rest, role-based access, strong authentication, input validation, separation of customer environments, secure backups, and monitored audit records. If HIPAA applies to the vendor’s role and data, assess the applicable Security Rule safeguards and document decisions about addressable specifications such as encryption. See 45 CFR § 164.312.

How can software updates change variant classifications?

Updates to algorithms, evidence rules, annotations, reference databases, or their underlying records can change the information used to prioritize or classify a variant. Record the software build and data versions for each analysis, test updates before release, and preserve enough provenance to reproduce or compare results. ClinVar’s version documentation explains why record versions matter when classifications or other record content change.

What information should variant analysis audit records contain?

Record the user or service, timestamp, action, sample or case identifier, input checksum and validation outcome, software and database versions, reference assembly, analysis result, and any manual change or export. Protect the records from unauthorized alteration and define retention according to applicable requirements and contracts. HIPAA requires audit controls for systems containing or using ePHI, but the six-year rule for required Security Rule documentation should not be confused with a universal retention period for every raw log. See 45 CFR § 164.312 and 45 CFR § 164.316.